Clinical Trials Using Poly ICLC

Clinical trials are research studies that involve people. The clinical trials on this list are studying Poly ICLC. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-22 of 22
  • H3.3K27M-specific Peptide Vaccine and Poly ICLC in Treating Patients with Newly Diagnosed HLA-A2 Positive, H3.3K27M Positive Diffuse Intrinsic Pontine Glioma or Other Newly Diagnosed Gliomas including Spinal Cord Tumors

    This pilot phase I trial studies the side effects of H3.3K27M-specific peptide vaccine and how well it works with poly ICLC in treating patients with newly diagnosed HLA-A2 positive, H3.3K27M positive diffuse intrinsic pontine glioma or other newly diagnosed glioma including spinal cord tumors. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Poly ICLC may boost the immune system. Giving H3.3K27M-specific peptide vaccine and poly ICLC may work better at treating HLA-A2 positive, H3.3K27M positive glioma.
    Location: 16 locations

  • A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

    The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.
    Location: 7 locations

  • A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

    This is an open-label, multicenter Phase 1 / 2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
    Location: 6 locations

  • Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

    This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).
    Location: 2 locations

  • Glioblastoma Multiforme Multipeptide Vaccine IMA950 and Poly ICLC with or without Varlilumab in Treating Patients with Newly Diagnosed or Recurrent Grade II Glioma

    This pilot randomized phase I trial studies the side effects of glioblastoma multiforme multipeptide vaccine IMA950 and poly ICLC and how well they work with or without varlilumab in treating patients with grade II glioma that is newly diagnosed or has come back (recurrent). Vaccines, such as glioblastoma multiforme multipeptide vaccine IMA950, made from peptides may help the body build an effective immune response to kill cancer cells. Immunosuppressive therapy, such as poly ICLC, is used to decrease the body’s immune response. Monoclonal antibodies, such as varlilumab, may interfere with the ability of cancer cells to grow and spread. Giving glioblastoma multiforme multipeptide vaccine IMA950 and poly ICLC with or without varlilumab may work in treating patients with glioma.
    Location: 2 locations

  • Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

    This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.
    Location: 2 locations

  • DEC-205 / NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and Epacadostat in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

    This partially randomized phase I / IIb trial studies the side effects and best dose of epacadostat in combination with DEC-205 / NY-ESO-1 fusion protein CDX-1401 and poly ICLC and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer who no longer have evidence of disease. Antigens (such as cancer / testis antigen [NY-ESO-1] protein) are found on many cancer cells. Vaccines made from NY-ESO-1 protein may cause the immune system to produce immune cells and antibodies that may help locate the NY-ESO-1 and / or cancer / testis antigen 2 (LAGE-1) antigens on cancer cells. By finding them, the immune system may then work to control or eliminate the remaining cancer cells. Epacadostat is an inhibitor of an enzyme called indoleamine 2,3 dioxygenase (IDO). This enzyme is produced by tumor cells to disable immune cells, and limit the efficacy of immune attack. Giving DEC-205 / NY-ESO-1 fusion protein CDX-1401 with poly ICLC and epacadostat may generate stronger and more long lasting anti-cancer immune responses in patients with ovarian, fallopian tube, and primary peritoneal cancer in remission.
    Location: 2 locations

  • Long Peptide Vaccine (LPV7) Plus TLR Agonists in Treating Participants with Resected Stage IIB-IV Melanoma

    This phase I / II trial studies the side effects and best combination of long peptide vaccine (LPV7) when combined with toll-like receptor agonists (TLR) such as tetanus peptide melanoma vaccine, incomplete Freund's adjuvant, poly ICLC and resiquimod gel in treating participants with stage IIb-IV melanoma that has been removed by surgery. Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells.
    Location: 2 locations

  • Flt3L, Radiation Therapy, Poly-ICLC, and Pembrolizumab in Treating Patients with Refractory Indolent Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, or Head and Neck Cancer

    This phase I / II trial studies the side effects of Flt3L, radiation therapy, poly-ICLC, and pembrolizumab and how well they work in treating patients with indolent non-Hodgkin's lymphoma, breast cancer that has spread to other places in the body, and head and neck cancer that do not respond to treatment. Flt3L causes the body to make more immune cells, specifically a type of immune cell called "dendritic cells". Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Poly-ICLC turns on the immune cells that have been brought to the tumor by Flt3L. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving Flt3L, radiation therapy, poly-ICLC, and pembrolizumab may work better in treating patients compared to Flt3L, radiation therapy, and poly-ICLC alone.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • A Vaccine (6MHP) with or without CDX-1127 for the Treatment of Stage IIB-IV Melanoma

    This phase I / II trial studies the side effects and how well a vaccine (6MHP) with or without CDX-1127 work for the treatment of stage IIB-IV melanoma. Vaccines, such as 6MHP, may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as CDX-1127, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see what effects 6MHP alone and in combination with CDX-1127 have on changes in the immune system.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Atezolizumab and PGV001 in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer

    This phase I trial studies the side effects and how well atezolizumab and PGV001 work in treating patients with urothelial cancer that has spread to nearby tissues or lymph nodes or to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PGV001 is a type of vaccine that is created based on analyzing an individual's tumor tissue. Giving atezolizumab and PGV001 may work better in treating patients with urothelial cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • DEC-205 / NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

    This phase I trial studies the side effects of DEC-205 / NY-ESO-1 fusion protein CDX-1401, poly ICLC, decitabine, and nivolumab in treating patients with myelodysplastic syndrome or acute myeloid leukemia. DEC-205 / NY-ESO-1 fusion protein CDX-1401 is a vaccine that may help the immune system specifically target and kill cancer cells. Poly ICLC may help stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Giving DEC-205 / NY-ESO-1 fusion protein CDX-1401, poly ICLC, decitabine, and nivolumab may work better in treating patients with myelodysplastic syndrome or acute myeloid leukemia.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Poly ICLC in Treating Patients with Prostate Cancer before Radical Prostatectomy

    This pilot phase I trial studies the best dose and best schedule of poly ICLC in treating patients with prostate cancer before radical prostatectomy. Poly ICLC may help the immune system identify prostate cancer as a foreign invader and attack it and help the body fight against cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Personalized Mutation-Derived Tumor Vaccine, Poly ICLC, and NovoTTF-200A in Treating Patients with Glioblastoma

    This phase I trial studies the side effects and how well personalized mutation-derived tumor vaccine, poly ICLC, and NovoTTF-200A work in treating patients with glioblastoma. Vaccines made from tumor peptide or antigen may help the body build an effective immune response to kill tumor cells that express specific antigen. Poly ICLC may help to stimulate the immune system. NovoTTF-200A produces tumor treatment fields which are low intensity electric fields that may slow or stop cancer cells from multiplying and may cause them to die. Giving personalized mutation-derived tumor vaccine, poly ICLC, and NovoTTF-200A may work better than poly ICLC alone in treating patients with glioblastoma.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Poly-ICLC-Assisted Tumor Lysate Vaccines in Treating Patients with Glioma

    This phase I trial studies how well poly-ICLC-assisted tumor lysate vaccines work in treating patients with glioma. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill glioma cells.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Montanide and / or Poly-ICLC with Oxidized Tumor Cell Lysate Vaccine and Sargramostim in Treating Patients with Advanced Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This randomized pilot early phase I trial studies montanide (montanide ISA 51 VG) and / or poly-ICLC with oxidized tumor cell lysate vaccine and sargramostim in treating patients with stage III-IV ovarian, primary peritoneal, or fallopian tube cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Biological therapies, such as montanide ISA 51 VG and poly-ICLC, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells. Giving montanide ISA 51 VG and / or poly-ICLC together with oxidized tumor cell lysate vaccine and sargramostim may be a better treatment for ovarian, primary peritoneal, or fallopian tube cancer.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

    The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for treatment of study subjects with advanced accessible solid tumors
    Location: 2 locations

  • Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery

    This phase II trial studies how well vaccine therapy and polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC) work in treating younger patients with low-grade gliomas that have come back after treatment and cannot be removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Giving HLA-A2-restricted synthetic glioma antigen peptides vaccine and tetanus toxoid vaccine with poly-ICLC may work better in treating younger patients with recurrent low-grade gliomas that cannot be removed by surgery.
    Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

  • Recombinant Flt3 Ligand, Poly-ICLC, and Radiation Therapy in Treating Patients with Untreated, Relapsed, or Refractory Low Grade B-Cell or Cutaneous T Cell Lymphoma

    This phase I / II trial studies how well recombinant Flt3 ligand, poly-ICLC, and radiation therapy work in treating patients low grade B-cell or cutaneous T cell lymphoma that has not been treated, has come back (relapsed), or does not respond to treatment (refractory). Recombinant Flt3 ligand vaccine may help the body make more immune cells called dendritic cells. The poly-ICLC vaccine stimulates the immune system by activating the dendritic cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving recombinant Flt3 ligand, poly-ICLC, and radiation therapy may work better at treating low grade B-cell or cutaneous T cell lymphoma.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma

    This pilot phase I trial studies the side effects and how well HLA-A2-restricted synthetic glioma antigen peptides vaccine and poly ICLC work in treating children with newly diagnosed high-grade glioma, brainstem glioma or low-grade glioma that has come back and can’t be removed by surgery. Vaccines made from small proteins called peptides may help the body build an effective immune response to kill tumor cells that express these glioma-associated peptides. Synthetic ribonucleic acids like poly ICLC may improve the effects of the vaccine. Giving HLA-A2-restricted synthetic glioma antigen peptides vaccine with poly ICLC may kill more tumor cells.
    Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

  • Personalized Synthetic Long Peptide Vaccine and Poly-ICLC in Treating Participants with Recurrent or Refractory Childhood Brain Tumors

    This phase I pilot trial studies the side effects and how well a personalized synthetic long peptide vaccine and poly-ICLC work in treating participants with childhood brain tumors that have come back or that aren't responding to treatment. The personalized synthetic long peptide vaccine is designed to target mutations specific to each person’s tumor that are discovered during genetic testing of the tumor. The vaccine may generate an immune response (the way the body fights viruses and other infections) to brain tumor cells. Poly-ICLC may have anti-tumor and antiviral effects. Giving a personalized synthetic long peptide vaccine with poly-ICLC may work better in treating participants with recurrent or refractory childhood brain tumors.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This randomized phase I / IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 16 locations